Aquestive Therapeutics Inc
NASDAQ:AQST
Intrinsic Value
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. [ Read More ]
The intrinsic value of one AQST stock under the Base Case scenario is 2.47 USD. Compared to the current market price of 4.26 USD, Aquestive Therapeutics Inc is Overvalued by 42%.
Valuation Backtest
Aquestive Therapeutics Inc
Run backtest to discover the historical profit from buying and selling AQST stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Aquestive Refinances Debt, Increases Revenue
2023-Q4 Earnings Call
Aquestive Therapeutics strengthened its financial position by renegotiating a $45 million debt refinancing deal with a 13.5% interest rate, which reduced near-term cash requirements and eliminated revenue or cash covenants and stock purchase warrants. This was paired with significant revenue growth, as Q4 2023 revenues rose to $13.2 million, a 24% increase compared to Q4 2022. The full-year 2023 revenues climbed 26% to $50.6 million, excluding prior year sales of Sympazan. The net loss decreased to $8.1 million in Q4 2023, improving from $12.4 million in Q4 2022. The guidance for 2024 sets revenue targets between $48 million and $51 million but does not include any sales from Libervant.
Balance Sheet Decomposition
Aquestive Therapeutics Inc
Current Assets | 41m |
Cash & Short-Term Investments | 23.9m |
Receivables | 8.5m |
Other Current Assets | 8.6m |
Non-Current Assets | 16.5m |
PP&E | 9.7m |
Intangibles | 1.3m |
Other Non-Current Assets | 5.4m |
Current Liabilities | 18.3m |
Accounts Payable | 8.9m |
Accrued Liabilities | 6.9m |
Other Current Liabilities | 2.5m |
Non-Current Liabilities | 145.6m |
Long-Term Debt | 27.5m |
Other Non-Current Liabilities | 118.1m |
Earnings Waterfall
Aquestive Therapeutics Inc
Revenue
|
50.6m
USD
|
Cost of Revenue
|
-20.8m
USD
|
Gross Profit
|
29.8m
USD
|
Operating Expenses
|
-44.9m
USD
|
Operating Income
|
-15.1m
USD
|
Other Expenses
|
7.2m
USD
|
Net Income
|
-7.9m
USD
|
Free Cash Flow Analysis
Aquestive Therapeutics Inc
What is Free Cash Flow?
AQST Profitability Score
Profitability Due Diligence
Aquestive Therapeutics Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
Score
Aquestive Therapeutics Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
AQST Solvency Score
Solvency Due Diligence
Aquestive Therapeutics Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Score
Aquestive Therapeutics Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AQST Price Targets Summary
Aquestive Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for AQST is 8.16 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.
Ownership
AQST Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
AQST Price
Aquestive Therapeutics Inc
Average Annual Return | -30.71% |
Standard Deviation of Annual Returns | 32.71% |
Max Drawdown | -93% |
Market Capitalization | 292m USD |
Shares Outstanding | 73 301 200 |
Percentage of Shares Shorted | 3.38% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 157 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered products to deliver molecules, providing alternatives to care therapies. The company is engaged in advancing a late-stage product pipeline focused on treating diseases of the central nervous system (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. The firm's CNS portfolio, which is focused on epilepsy includes Sympazan and Libervant. The active programs in its complex molecule pipeline portfolio are: AQST-109-SF, AQST-108-SF, and AQST-108-SF. Its PharmFilm technology develops medicines that offer non-invasive delivery, customized suitability for patients with dysphagia, or trouble swallowing, can be administered without water and ensures consistent therapeutic dosing. PharmFilm is comprised of polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs) and excipients in place.
Contact
IPO
Employees
Officers
The intrinsic value of one AQST stock under the Base Case scenario is 2.47 USD.
Compared to the current market price of 4.26 USD, Aquestive Therapeutics Inc is Overvalued by 42%.